HOME >> BIOLOGY >> NEWS
HYPER-CEST MRI breaks new ground in molecular imaging

T technology, which was developed as a contrast method for boosting the MRI contrast from protons. CEST is based on the exchange of protons that takes place between water molecules and other molecules in the body. (Approximately 60-percent of the human body and 90-percent of the blood is water.) During an MRI session, these exchanging protons can be selectively labeled with the RF pulse. Comparing MRI images taken with and without CEST labeling yields images with meaningful bright contrasts. While effective under certain conditions, CEST is limited by the fast relaxation time of protons, which necessitates the need for large magnetic fields to decrease relaxation effects and increase the difference between saturated and non-saturated MRI signals. It also requires a relatively large amount of the CEST agent to generate significant contrast enhancement.

Hyperpolarized xenon has a much longer relaxation time than protons, which means that the enhanced MRI signal is not only stronger, but lasts much longer. The MRI signal obtained directly from the xenon biosensors is hundreds of times smaller than the easily detected signal obtained from a pool of free xenon dissolved in the rest of the sample. The HYPER-CEST images are based on the free xenon signal rather than direct detection of the biosensors which leads to the high sensitivity of the technique.

Another huge advantage, as Lowery explained, is that "there is no xenon naturally present in body, so we don't have to fish out a small change in an MRI signal with a high background like other MRI contrast agents. In that sense, HYPER-CEST is more like a PET (Positron Emission Tomography) probe. Because multiple xenon biosensors can be used to detect different targets at the same time, HYPER-CEST is also like quantum dots, where different colors of dots can be used to simultaneously report different analytes. However, unlike quantum dots, our xenon agents can be detected deep within the body."


'"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
19-Oct-2006


Page: 1 2 3 4 5 6 7

Related biology news :

1. No magic tomato? Study breaks link between lycopene and prostate cancer prevention
2. Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks
3. Ebola outbreaks killing thousands of gorillas and chimpanzees
4. Lost cuckoo breaks its silence
5. Mathematical model predicts cholera outbreaks
6. UGA study underscores importance of rapid reponse in curtailing disease outbreaks
7. Genetic repair mechanism clears the way for sealing DNA breaks
8. New study shows how genetic repair mechanism helps seal DNA breaks
9. New textbook uses real disease outbreaks to teach undergraduate microbiology
10. New treatment option breaks Leukemias resistance to chemotherapy, radiation therapy
11. Study finds key distinction between outbreaks that die out and epidemics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: HYPER CEST MRI breaks new ground molecular imaging

(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) fertilizers ... high prices in 2008. However, the situation has stabilised ... gaining momentum now. , To date, the world annual ... thousand tonnes. No considerable growth was registered in the ... during 2012-2013, registering 11% growth as against the period ...
(Date:3/27/2015)... Mich. , March 27, 2015  Neogen Corporation ... LLC, has adopted a prearranged trading plan in accordance ... Herbert , Chairman and CEO of Neogen Corporation, is ... of Neogen Corporation common stock. Herbert does ... disclosure was appropriate. The filing is only for a ...
(Date:3/27/2015)... 2015  Peter Walter was chosen as winner of ... work on how proteins are transported between cellular compartments ... that cells use to handle stress tied to the ... of biochemistry at the University of California, San Francisco. ... of human diseases related to defective protein folding and ...
(Date:3/27/2015)... , March 27, 2015 WuXi ... leading open-access R&D capability and technology platform company ... industries, announced today that an Investigational New Drug ... antibody for rheumatoid arthritis has been accepted for ... (CFDA).  In September 2012, MedImmune, ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Neogen CEO adopts 10b5-1 Trading Plan 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3
Cached News: